The human genome encodes several hundred E3 ligases—the enzymes that decide which proteins a cell destroys. Drug developers have so far harnessed a small number of them. In a new review in Molecular Cell, researchers at Karolinska Institutet and the University of Verona argue that the rest of these E3 ligases are where the next generation of cancer drugs will be found.